Great venue in Nice for the 4th Joint Meeting on Lung Cancer organized by Paul Hofman ⁦Marius.Ilié⁩ John Heymach ⁦MD Anderson Cancer Center⁩

New #JITC short report: FGF/FGFR genomic amplification as a predictive biomarker for immune checkpoint blockade resistance: a short report bit.ly/3QcopkZ Nicolas Roussot, MD, PhD student GHIRINGHELLI Francois

The U1231 CTM and US58 BioSand scientific day is starting with ou Director’s GHIRINGHELLI Francois welcoming! Looking forward to hearing our members’ exciting talks and to discover their posters ! Inserm @univbourgogne CGFL

Happy to share our new article on AI to predict outcome in localized CRC. Machine learning a valuable strategy to analyse CD3+ immune contexture Machine learning evaluation of immune infiltrate through digital tumou... sciencedirect.com/science/articl…

Happy to share results of our new clinical trial:nature.com/articles/s4139… Safety and efficacy of trifluridine/tipiracil +/− bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial Let me explain you the story 1/9

🔬 For patients with metastatic colorectal cancer (mCRC), chemotherapy resistance often leaves limited options.This phase 1 study evaluates a novel approach: combining trifluridine/tipiracil (FTD/TPI) and bevacizumab with XB2001, an IL-1α-targeting monoclonal antibody.

🔥 Chronic inflammation fuels tumor growth, angiogenesis, and immune evasion in metastatic colorectal cancer (mCRC). IL-1α, , is overexpressed in colorectal tumors and linked to poor prognosis. Neutralizing IL-1α, aims to suppress inflammation and enhance immune response (3/9)

🧪 This single-center phase 1 trial tested the safety, tolerability, and efficacy of XB2001 in combination with FTD/TPI and bevacizumab in chemoresistant mCRC pts. 🔹 17 patients participated. 🔹 A dose-escalation design evaluated XB2001 at 250, 500, and 1000 mg every 2 wks (4/9)

📊 The results of the trial are promising! ✔️ Disease control rate: 76%. ✔️ Progression-free survival: 9.4 months ✔️ Most common side effects: manageable nausea, neutropenia, and hypertension. Notably, a reduction in serum IL-6, was strongly associated with better outcome (5/9)

Biomarkers reveals: ✔️ Patients with high baseline CD8+ T cells and PD-L1 in their tumors responded better. ✔️ Reduction in IL-6 levels after treatment correlated with improved PFS By targeting inflammation and boosting immune activity, XB2001 shows promise in reshaping the TME.

💊 The pharmacokinetics analysis of XB2001 showed: ✔️ A dose-dependent increase in drug concentration. ✔️ Stable plasma levels at the recommended phase 2 dose (1000 mg). ✔️ Minimal anti-drug antibody formation This data supports the safety and efficacy of the 1000 mg dose (7/9)

🔮 The integration of XB2001 with FTD/TPI and bevacizumab marks a promising step forward in mCRC . This study suggests: ✔️ IL-1α targeting can improve outcomes in chemo-resistant mCRC. ✔️ The TME (inflammation, immune infiltration) plays a crucial role in TTT efficacy (8/9)

Phase 2 trial which is ongoing (more than 100 patients included) will explore XB2001's potential in randomized settings. The future of personalized cancer treatment is bright! (9/9)

Very sad day for Americans and the world, a calamity: Trump orders US to leave World Health Organization bbc.com/news/articles/…

Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study (1/3)

Happy to share our new paper showing that bevacizumab could reverse resistance to ICI in NSCLC. Atezolizumab+ bevacizumab compare favorable to docetaxel with less toxicity and higher OR and PFS (2/3)

These data corrobate the Ivonescimab data showing that targeting VEGF is important in NSCLC. Additional biomarker study will come soon jitc.bmj.com/content/13/8/e… (3/3)